Atopic Dermatitis

Nektar Therapeutics has completed target enrollment for its phase 2b study of rezpegaldesleukin for the treatment of patients with moderate to severe atopic dermatitis, the company announced in a press release.

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating the efficacy of the ointment’s 2% formulation, the company announced in a press release.

Allergy and immunology lost a pioneer last summer with the death of Marcus Maurer, MD, executive director of the Institute of Allergology at Charité University Medicine, Berlin.

Severe disease, male sex, family history and prenatal factors were significantly associated with an increased risk for atopic march progression in infants with atopic dermatitis, according to a study.

BOSTON — Managing food allergies should involve more than just allergen avoidance, according to a presentation at the American College of Allergy, Asthma & Immunology Annual Scientific Meeting.

The year 2024 was important for skin disorders with many innovations and breakthroughs.

The popular atopic dermatitis drug dupilumab has been found to be associated with an increased risk for cutaneous T-cell lymphoma in treated patients. It was the top dermatitis article in dermatology this year.

Patients who used dupilumab for atopic dermatitis had significantly lower risks for internal malignancies than patients using other therapies, according to a study published in The Journal of Allergy and Clinical Immunology: In Practice.

The FDA has approved Nemluvio, in conjunction with topical corticosteroids and/or calcineurin inhibitors, for the treatment of moderate to severe atopic dermatitis in patients aged 12 years and older, Galderma announced in a press release.

The FDA has approved Vtama cream 1% for atopic dermatitis in adults and children aged 2 years and older, Organon announced in a press release.